Immunovia Publishes the Annual Report for the Financial Year 2018

Immunovia Publishes the Annual Report for the Financial Year 2018

PR Newswire

LUND, Sweden, March 4, 2019

LUND, Sweden, March 4, 2019 /PRNewswire/ -- Immunovia has today published the annual report for 2018 in Swedish. It is available on Immunovia's website.

Mats Grahn, CEO, comments: "We entered 2018 with the continued mission to develop and validate accurate blood-based diagnostic tests and moved towards the exciting activities to commercialize those efforts. We completed the expansion of our production and sample testing facilities, IMMray™ Dx Laboratories, at our headquarters in Lund, Sweden, we advanced our important clinical collaborations and entered into new ones, our shares began trading on Nasdaq Stockholm main list and embarked on a new and inspiring initiative to partner with several prominent patient organizations to sponsor fundraising walks to help build awareness of the IMMray™ PanCan-d test and educate on the risk factors and the symptoms for pancreatic cancer."

Major highlights include:

The Swedish annual report is available on Immunovia's website: and is also attached below.

For more information, please contact:

Julie Silber

Director of Investor Relations


Tel: +46-7-93-486-277

About Immunovia

Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia's strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood-based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring.


Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit

This information was brought to you by Cision,c2755598

The following files are available for download:

Immunovia Annual Report 2018 Swedish version

Voltar noticias em Inglês